The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Genetic Disorders Drug-Global Market Insights and Sales Trends 2024
Synopsis
Genetic Disorders Drugs are genetic materials such as DNA and RNA delivered into the body as a therapeutic. They are a promising new class of medicine that was not possible even a short time ago.
The global Genetic Disorders Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Genetic Disorders Drug in various end use industries. The expanding demands from the Clinic and Hospital, are propelling Genetic Disorders Drug market. Cystic Fibrosis (CF), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Duchenne Muscular Dystrophy (DMD) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Genetic Disorders Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Genetic Disorders Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Genetic Disorders Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Genetic Disorders Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Genetic Disorders Drug covered in this report include Sanofi, Vertex, Takeda, Amgen, GW Pharmaceuticals, Pfizer, BioMarin and Sarepta, etc.
The global Genetic Disorders Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi
Vertex
Takeda
Amgen
GW Pharmaceuticals
Pfizer
BioMarin
Sarepta
Global Genetic Disorders Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Genetic Disorders Drug market, Segment by Type:
Cystic Fibrosis (CF)
Duchenne Muscular Dystrophy (DMD)
Lysosomal Storage Disease (LSD)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Global Genetic Disorders Drug market, by Application
Clinic
Hospital
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Genetic Disorders Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Genetic Disorders Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Genetic Disorders Drugs are genetic materials such as DNA and RNA delivered into the body as a therapeutic. They are a promising new class of medicine that was not possible even a short time ago.
The global Genetic Disorders Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Genetic Disorders Drug in various end use industries. The expanding demands from the Clinic and Hospital, are propelling Genetic Disorders Drug market. Cystic Fibrosis (CF), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Duchenne Muscular Dystrophy (DMD) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Genetic Disorders Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Genetic Disorders Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Genetic Disorders Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Genetic Disorders Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Genetic Disorders Drug covered in this report include Sanofi, Vertex, Takeda, Amgen, GW Pharmaceuticals, Pfizer, BioMarin and Sarepta, etc.
The global Genetic Disorders Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi
Vertex
Takeda
Amgen
GW Pharmaceuticals
Pfizer
BioMarin
Sarepta
Global Genetic Disorders Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Genetic Disorders Drug market, Segment by Type:
Cystic Fibrosis (CF)
Duchenne Muscular Dystrophy (DMD)
Lysosomal Storage Disease (LSD)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Global Genetic Disorders Drug market, by Application
Clinic
Hospital
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Genetic Disorders Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Genetic Disorders Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Genetic Disorders Drug Market Overview
1.1 Genetic Disorders Drug Product Overview
1.2 Genetic Disorders Drug Market Segment by Type
1.2.1 Cystic Fibrosis (CF)
1.2.2 Duchenne Muscular Dystrophy (DMD)
1.2.3 Lysosomal Storage Disease (LSD)
1.2.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
1.3 Global Genetic Disorders Drug Market Size by Type
1.3.1 Global Genetic Disorders Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Genetic Disorders Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Genetic Disorders Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Genetic Disorders Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Genetic Disorders Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Genetic Disorders Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Genetic Disorders Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Genetic Disorders Drug Sales Breakdown by Type (2018-2023)
2 Global Genetic Disorders Drug Market Competition by Company
2.1 Global Top Players by Genetic Disorders Drug Sales (2018-2023)
2.2 Global Top Players by Genetic Disorders Drug Revenue (2018-2023)
2.3 Global Top Players by Genetic Disorders Drug Price (2018-2023)
2.4 Global Top Manufacturers Genetic Disorders Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Genetic Disorders Drug Market Competitive Situation and Trends
2.5.1 Genetic Disorders Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Genetic Disorders Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Genetic Disorders Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Genetic Disorders Drug Market
2.8 Key Manufacturers Genetic Disorders Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Genetic Disorders Drug Status and Outlook by Region
3.1 Global Genetic Disorders Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Genetic Disorders Drug Historic Market Size by Region
3.2.1 Global Genetic Disorders Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Genetic Disorders Drug Sales in Value by Region (2018-2023)
3.2.3 Global Genetic Disorders Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Genetic Disorders Drug Forecasted Market Size by Region
3.3.1 Global Genetic Disorders Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Genetic Disorders Drug Sales in Value by Region (2024-2029)
3.3.3 Global Genetic Disorders Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Genetic Disorders Drug by Application
4.1 Genetic Disorders Drug Market Segment by Application
4.1.1 Clinic
4.1.2 Hospital
4.2 Global Genetic Disorders Drug Market Size by Application
4.2.1 Global Genetic Disorders Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Genetic Disorders Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Genetic Disorders Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Genetic Disorders Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Genetic Disorders Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Genetic Disorders Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Genetic Disorders Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Genetic Disorders Drug Sales Breakdown by Application (2018-2023)
5 North America Genetic Disorders Drug by Country
5.1 North America Genetic Disorders Drug Historic Market Size by Country
5.1.1 North America Genetic Disorders Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Genetic Disorders Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Genetic Disorders Drug Sales in Value by Country (2018-2023)
5.2 North America Genetic Disorders Drug Forecasted Market Size by Country
5.2.1 North America Genetic Disorders Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Genetic Disorders Drug Sales in Value by Country (2024-2029)
6 Europe Genetic Disorders Drug by Country
6.1 Europe Genetic Disorders Drug Historic Market Size by Country
6.1.1 Europe Genetic Disorders Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Genetic Disorders Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Genetic Disorders Drug Sales in Value by Country (2018-2023)
6.2 Europe Genetic Disorders Drug Forecasted Market Size by Country
6.2.1 Europe Genetic Disorders Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Genetic Disorders Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Genetic Disorders Drug by Region
7.1 Asia-Pacific Genetic Disorders Drug Historic Market Size by Region
7.1.1 Asia-Pacific Genetic Disorders Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Genetic Disorders Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Genetic Disorders Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Genetic Disorders Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Genetic Disorders Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Genetic Disorders Drug Sales in Value by Region (2024-2029)
8 Latin America Genetic Disorders Drug by Country
8.1 Latin America Genetic Disorders Drug Historic Market Size by Country
8.1.1 Latin America Genetic Disorders Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Genetic Disorders Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Genetic Disorders Drug Sales in Value by Country (2018-2023)
8.2 Latin America Genetic Disorders Drug Forecasted Market Size by Country
8.2.1 Latin America Genetic Disorders Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Genetic Disorders Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Genetic Disorders Drug by Country
9.1 Middle East and Africa Genetic Disorders Drug Historic Market Size by Country
9.1.1 Middle East and Africa Genetic Disorders Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Genetic Disorders Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Genetic Disorders Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Genetic Disorders Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Genetic Disorders Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Genetic Disorders Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Sanofi
10.1.1 Sanofi Company Information
10.1.2 Sanofi Introduction and Business Overview
10.1.3 Sanofi Genetic Disorders Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Sanofi Genetic Disorders Drug Products Offered
10.1.5 Sanofi Recent Development
10.2 Vertex
10.2.1 Vertex Company Information
10.2.2 Vertex Introduction and Business Overview
10.2.3 Vertex Genetic Disorders Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Vertex Genetic Disorders Drug Products Offered
10.2.5 Vertex Recent Development
10.3 Takeda
10.3.1 Takeda Company Information
10.3.2 Takeda Introduction and Business Overview
10.3.3 Takeda Genetic Disorders Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Takeda Genetic Disorders Drug Products Offered
10.3.5 Takeda Recent Development
10.4 Amgen
10.4.1 Amgen Company Information
10.4.2 Amgen Introduction and Business Overview
10.4.3 Amgen Genetic Disorders Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Amgen Genetic Disorders Drug Products Offered
10.4.5 Amgen Recent Development
10.5 GW Pharmaceuticals
10.5.1 GW Pharmaceuticals Company Information
10.5.2 GW Pharmaceuticals Introduction and Business Overview
10.5.3 GW Pharmaceuticals Genetic Disorders Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 GW Pharmaceuticals Genetic Disorders Drug Products Offered
10.5.5 GW Pharmaceuticals Recent Development
10.6 Pfizer
10.6.1 Pfizer Company Information
10.6.2 Pfizer Introduction and Business Overview
10.6.3 Pfizer Genetic Disorders Drug Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Pfizer Genetic Disorders Drug Products Offered
10.6.5 Pfizer Recent Development
10.7 BioMarin
10.7.1 BioMarin Company Information
10.7.2 BioMarin Introduction and Business Overview
10.7.3 BioMarin Genetic Disorders Drug Sales, Revenue and Gross Margin (2018-2023)
10.7.4 BioMarin Genetic Disorders Drug Products Offered
10.7.5 BioMarin Recent Development
10.8 Sarepta
10.8.1 Sarepta Company Information
10.8.2 Sarepta Introduction and Business Overview
10.8.3 Sarepta Genetic Disorders Drug Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Sarepta Genetic Disorders Drug Products Offered
10.8.5 Sarepta Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Genetic Disorders Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Genetic Disorders Drug Industrial Chain Analysis
11.4 Genetic Disorders Drug Market Dynamics
11.4.1 Genetic Disorders Drug Industry Trends
11.4.2 Genetic Disorders Drug Market Drivers
11.4.3 Genetic Disorders Drug Market Challenges
11.4.4 Genetic Disorders Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Genetic Disorders Drug Distributors
12.3 Genetic Disorders Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
